PE20090838A1 - Pontenciacion de quimioterapia de cancer - Google Patents

Pontenciacion de quimioterapia de cancer

Info

Publication number
PE20090838A1
PE20090838A1 PE2008001054A PE2008001054A PE20090838A1 PE 20090838 A1 PE20090838 A1 PE 20090838A1 PE 2008001054 A PE2008001054 A PE 2008001054A PE 2008001054 A PE2008001054 A PE 2008001054A PE 20090838 A1 PE20090838 A1 PE 20090838A1
Authority
PE
Peru
Prior art keywords
pirrolo
benzodiazepine
dioxo
piperidinyl
tetrahydro
Prior art date
Application number
PE2008001054A
Other languages
English (en)
Inventor
Aktham Aburub
Marcio Chedid
Thomas Albert Engler
Venkatraghavan Vasu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39737054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090838(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20090838A1 publication Critical patent/PE20090838A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN AGENTE QUIMIOTERAPEUTICO SELECCIONADO DE CISPLATINO, PEMETREXED, GEMCITABINA, ETOPOSIDO, DOXORUBICINA, ENTRE OTROS Y 7-(2,5-DIHIDRO-4-IMIDAZO[1,2-a]-PIRIDIN-3-IL-2,5-DIOXO-1H-PIRROL-3-IL)-9-FLUORO-1,2,3,4-TETRAHIDRO-2-(1-PIPERIDINIL-CARBONIL)PIRROLO[3,2,1-jk][1,4]BENZODIAZEPINA. REFERIDA ADEMAS AL PROCESO QUE COMPRENDE: A) AGREGAR 7-(2,5-DIHIDRO-4-IMIDAZO[1,2-a]-PIRIDIN-3-IL-2,5-DIOXO-1H-PIRROL-3-IL)-9-FLUORO-1,2,3,4-TETRAHIDRO-2-(1-PIPERIDINIL-CARBONIL)PIRROLO[3,2,1-jk][1,4]BENZODIAZEPINA A UNA SOLUCION ACUOSA A UN pH MENOR DE 5.5 QUE CONTIENE AL MENOS 1 EQUIVALENTE MOLAR DE SBE7-ß-CD Y UN AMORTIGUADOR DE PREFERENCIA ACIDO TARTARICO; B) AJUSTAR EL pH DE LA SOLUCION RESULTANTE ENTRE 2.5-3.5 CON UN ACIDO O BASE; C) OPCIONALMENTE LIOFILIZAR LA SOLUCION. DICHA COMPOSICION DE RECONSTITUCION CON AGUA PARA INYECCION O INFUSION ES UTIL EN EL TRATAMIENTO DE CANCER DE OVARIO, CANCER DE PULMON, CANCER COLORECTAL
PE2008001054A 2007-07-02 2008-06-19 Pontenciacion de quimioterapia de cancer PE20090838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94751207P 2007-07-02 2007-07-02

Publications (1)

Publication Number Publication Date
PE20090838A1 true PE20090838A1 (es) 2009-07-02

Family

ID=39737054

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001054A PE20090838A1 (es) 2007-07-02 2008-06-19 Pontenciacion de quimioterapia de cancer

Country Status (23)

Country Link
US (2) US8318713B2 (es)
EP (1) EP2173348B1 (es)
JP (2) JP5551589B2 (es)
KR (1) KR101230085B1 (es)
CN (2) CN102772416A (es)
AR (1) AR067112A1 (es)
AU (1) AU2008270732B2 (es)
BR (1) BRPI0813789A2 (es)
CA (1) CA2691587C (es)
CL (2) CL2008001848A1 (es)
EA (2) EA023697B1 (es)
ES (1) ES2561202T3 (es)
HK (1) HK1141236A1 (es)
IL (2) IL202237A (es)
MA (1) MA31677B1 (es)
MX (1) MX2009013449A (es)
MY (1) MY154472A (es)
NZ (1) NZ581355A (es)
PE (1) PE20090838A1 (es)
TW (1) TWI428132B (es)
UA (1) UA97400C2 (es)
WO (1) WO2009006043A2 (es)
ZA (1) ZA200908725B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
EA018933B1 (ru) 2009-04-14 2013-11-29 Эли Лилли Энд Компани Производное бензодиазепина для лечения гематопоэтических новообразований и лейкоза
WO2013044219A1 (en) * 2011-09-22 2013-03-28 Bind Biosciences Methods of treating cancers with therapeutic nanoparticles
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
JP6364546B2 (ja) * 2015-04-30 2018-07-25 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10016507B2 (en) * 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP1788086A1 (en) * 1997-03-17 2007-05-23 Human Genome Sciences, Inc. Death Domain Containing Receptor 5
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
BR0308243B1 (pt) 2002-03-05 2014-08-26 Lilly Co Eli Derivados de purina como inibidores de quinase, seu uso para tratar diabetes e doença de alzheimer, para estimular deposição óssea e inibir gsk-3, bem como formulação farmacêutica compreendendo os referidos derivados
EP1539756B1 (en) 2002-09-19 2007-11-14 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
AU2005262925B2 (en) * 2004-07-09 2011-01-20 Agency For Science, Technology And Research Modulation of GSK-3beta and method of treating proliferative disorders
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
WO2006119464A1 (en) * 2005-05-04 2006-11-09 University Of South Florida Predicting treatment response in cancer subjects
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化

Also Published As

Publication number Publication date
AU2008270732B2 (en) 2013-01-31
EP2173348B1 (en) 2015-12-09
MY154472A (en) 2015-06-30
CN101743005B (zh) 2013-06-12
WO2009006043A2 (en) 2009-01-08
EP2173348A2 (en) 2010-04-14
EA018447B1 (ru) 2013-08-30
CA2691587C (en) 2013-09-24
US20130039996A1 (en) 2013-02-14
EA201070085A1 (ru) 2010-04-30
JP5551589B2 (ja) 2014-07-16
MX2009013449A (es) 2010-01-15
MA31677B1 (fr) 2010-09-01
ES2561202T3 (es) 2016-02-25
KR101230085B1 (ko) 2013-02-05
EA201201155A1 (ru) 2014-11-28
US20100166884A1 (en) 2010-07-01
UA97400C2 (uk) 2012-02-10
US8648063B2 (en) 2014-02-11
ZA200908725B (en) 2011-02-23
AU2008270732A1 (en) 2009-01-08
TWI428132B (zh) 2014-03-01
TW200911272A (en) 2009-03-16
HK1141236A1 (en) 2010-11-05
CN102772416A (zh) 2012-11-14
WO2009006043A3 (en) 2009-04-16
CL2008001848A1 (es) 2009-05-29
CN101743005A (zh) 2010-06-16
AR067112A1 (es) 2009-09-30
KR20100017984A (ko) 2010-02-16
CL2011003046A1 (es) 2012-08-24
IL202237A0 (en) 2010-06-16
JP2010532364A (ja) 2010-10-07
IL202237A (en) 2014-05-28
BRPI0813789A2 (pt) 2014-12-30
EA023697B1 (ru) 2016-07-29
US8318713B2 (en) 2012-11-27
IL218443A0 (en) 2012-04-30
JP2014114297A (ja) 2014-06-26
CA2691587A1 (en) 2009-01-08
NZ581355A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
PE20090838A1 (es) Pontenciacion de quimioterapia de cancer
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
AR069788A1 (es) Formulacion de anticuerpo anti- cd20 humano y usos de la misma
PE20120777A1 (es) Combinacion de un inhibidor de nucleosido polimerasa con un inhibidor de proteasa macrociclica y su uso en el tratamiento de hepatitis c, fibrosis hepatica y funcion hepatica alterada
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
PA8524901A1 (es) Forma de dosificaciòn de fàrmaco activada por hidrogel
CL2007000797A1 (es) Composicion farmaceutica que comprende entre alrededor de 1 y 150 mg/ml de humab igf-1r, entre alrededor de 0,001 y 1% de al menos un humectante, entre alredededor de 1 y 100 mm de un tapon a un ph entre alrededor de 5 y 7; y uso para el tratamiento de cancer de mama, cancer de pulmon y de prostata
TW200716631A (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
MX2019013643A (es) Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
CL2008001122A1 (es) Compuestos derivados de imidazo[1,2,3-ij]-1,8-naftiridin-4,9-diona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
AR065246A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos
WO2007026024A3 (en) Benzodiazepines as hcv inhibitors
RS54904B1 (sr) Antibakterijske farmaceutske kompozicije
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
CL2011000729A1 (es) Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
JP2010532364A5 (es)
WO2009064681A3 (en) Liquid compositions comprising valsartan
SG10201809189UA (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use

Legal Events

Date Code Title Description
FC Refusal